Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 7/20 | 0.45 |
| ▸ | NPY4R | P50391 | 10/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.41 |
| ▸ | NPY1R | P25929 | 7/20 | 0.41 |
| ▸ | NPY2R | P49146 | 5/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961412 | 0.99 | QRFPR (0.46) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL3961387 | 0.99 | QRFPR (0.46) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29569172 | 0.99 | QRFPR (0.46) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30062951 | 0.95 | SLC15A2 (0.44) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29556238 | 0.95 | C3AR1 (0.41) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30078669 | 0.95 | C3AR1 (0.41) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29435094 | 0.94 | SLC15A2 (0.45) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL15757149 | 0.94 | C3AR1 (0.42) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL15757154 | 0.94 | C3AR1 (0.42) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29533805 | 0.92 | QRFPR (0.43) | QRFPRNPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | claimed |
| US-20230285456-A1 | TUMOR THERAPY COMPOSITIONS AND METHODS | UNM RAINFOREST INNOVATIONS | 2023-09-14 | — | — | US | disclosed |
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | QRFPR 1385/4885NPY4R 2691/4885NPY5R 2137/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | QRFPR 1385/4885NPY4R 2691/4885NPY5R 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.